Chemomab Therapeutics Ltd DRC Net Assets
Chemomab Therapeutics Ltd DRC net assets. Based on the latest financial reports, Chemomab Therapeutics Ltd DRC (CMMB) has net assets worth $8.68 Million USD as of June 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($10.24 Million) and total liabilities ($1.55 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore net asset momentum of Chemomab Therapeutics Ltd DRC to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $8.68 Million |
| % of Total Assets | 84.83% |
| Annual Growth Rate | 10.7% |
| 5-Year Change | -79.93% |
| 10-Year Change | 274.56% |
| Growth Volatility | 154.68 |
Net Assets of Chemomab Therapeutics Ltd DRC (2012–2025)
Net assets of Chemomab Therapeutics Ltd DRC from 2012 to 2025. This chart illustrates how Chemomab Therapeutics Ltd DRC's net assets have evolved over time, based on quarterly financial data. See CMMB net asset quality score to measure how much of total assets are equity-financed.
Annual Net Assets for Chemomab Therapeutics Ltd DRC (2012–2025)
The table below shows the annual net assets of Chemomab Therapeutics Ltd DRC from 2012 to 2025. For live market cap and overall valuation, see Chemomab Therapeutics Ltd DRC stock valuation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $12.33 Million | -8.89% |
| 2024-12-31 | $13.54 Million | -20.36% |
| 2023-12-31 | $17.00 Million | -53.08% |
| 2022-12-31 | $36.22 Million | -41.07% |
| 2021-12-31 | $61.47 Million | +469.02% |
| 2020-12-31 | $10.80 Million | -27.55% |
| 2019-12-31 | $14.91 Million | +52.06% |
| 2018-12-31 | $9.80 Million | +1710.02% |
| 2017-12-31 | $-609.00K | -118.49% |
| 2016-12-31 | $3.29 Million | +53.52% |
| 2015-12-31 | $2.14 Million | -34.82% |
| 2012-12-31 | $3.29 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Chemomab Therapeutics Ltd DRC's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 113773100.0% over the analyzed period, indicating profitable operations and earnings retention.
Chemomab Therapeutics Ltd DRC Net Assets Breakdown (December 2025)
Chemomab Therapeutics Ltd DRC net assets breakdown by equity component as of December 2025.
| Component | Amount | Percentage |
|---|---|---|
| Other Components | $123.95 Million | 1004.96% |
| Total Equity | $12.33 Million | 100.00% |
Chemomab Therapeutics Ltd DRC Competitors by Market Cap
The table below lists competitors of Chemomab Therapeutics Ltd DRC ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Green Earth Group N.V.
AS:HWK
|
$8.65 Million |
|
Erria A/S
CO:ERRIA
|
$8.65 Million |
|
Flexidynamic Holdings Bhd
KLSE:0231
|
$8.65 Million |
|
Suzhou Goldengreen Technologies Ltd
SHE:002808
|
$8.65 Million |
|
COSCIENS Biopharma Inc.
NASDAQ:CSCI
|
$8.64 Million |
|
YLI Holdings Bhd
KLSE:7014
|
$8.64 Million |
|
Swissnet AG
F:81D
|
$8.63 Million |
|
CS Corporation
KQ:065770
|
$8.63 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Chemomab Therapeutics Ltd DRC's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 13,537,000 to 12,333,808, a change of -1,203,192 (-8.9%).
- Net loss of 8,995,000 reduced equity.
- New share issuances of 7,145,000 increased equity.
- Other factors increased equity by 646,808.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-8.99 Million | -72.93% |
| Share Issuances | $7.14 Million | +57.93% |
| Other Changes | $646.81K | +5.24% |
| Total Change | $- | -8.89% |
Book Value vs Market Value Analysis
This analysis compares Chemomab Therapeutics Ltd DRC's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.61x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has increased from 0.00x to 0.61x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2012-12-31 | $438.22 | $1.18 | x |
| 2015-12-31 | $37.68 | $1.18 | x |
| 2016-12-31 | $48.48 | $1.18 | x |
| 2017-12-31 | $-53.98 | $1.18 | x |
| 2018-12-31 | $62.09 | $1.18 | x |
| 2019-12-31 | $28.74 | $1.18 | x |
| 2020-12-31 | $465.88 | $1.18 | x |
| 2021-12-31 | $23.70 | $1.18 | x |
| 2022-12-31 | $12.73 | $1.18 | x |
| 2023-12-31 | $5.79 | $1.18 | x |
| 2024-12-31 | $66.72 | $1.18 | x |
| 2025-12-31 | $1.93 | $1.18 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Chemomab Therapeutics Ltd DRC utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -72.93%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.12x
- Recent ROE (-72.93%) is below the historical average (6.06%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2012 | 734.82% | 0.00% | 0.00x | 2.88x | $23.85 Million |
| 2015 | -349.71% | 0.00% | 0.00x | 1.64x | $-7.72 Million |
| 2016 | -143.74% | 0.00% | 0.00x | 1.72x | $-5.06 Million |
| 2017 | 0.00% | 0.00% | 0.00x | 0.00x | $-9.75 Million |
| 2018 | 135.43% | 0.00% | 0.00x | 1.30x | $12.30 Million |
| 2019 | 219.22% | 0.00% | 0.00x | 1.60x | $25.89 Million |
| 2020 | -108.22% | 0.00% | 0.00x | 1.15x | $-12.77 Million |
| 2021 | -20.31% | 0.00% | 0.00x | 1.05x | $-18.63 Million |
| 2022 | -76.32% | 0.00% | 0.00x | 1.19x | $-31.27 Million |
| 2023 | -142.50% | 0.00% | 0.00x | 1.30x | $-25.92 Million |
| 2024 | -103.01% | 0.00% | 0.00x | 1.25x | $-15.30 Million |
| 2025 | -72.93% | 0.00% | 0.00x | 1.12x | $-10.23 Million |
Industry Comparison
This section compares Chemomab Therapeutics Ltd DRC's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $154,916,114
- Average return on equity (ROE) among peers: -15.75%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Chemomab Therapeutics Ltd DRC (CMMB) | $8.68 Million | 734.82% | 0.18x | $8.65 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $26.78 Million |
| Abcellera Biologics Inc (ABCL) | $1.06 Billion | -15.42% | 0.29x | $3.53 Billion |
| Abeona Therapeutics Inc (ABEO) | $-5.83 Million | 0.00% | 0.00x | $243.03 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $225.18 Million | -44.68% | 0.02x | $16.93 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $67.00 Million | -21.42% | 0.32x | $1.41 Billion |
| Arbutus Biopharma Corp (ABUS) | $40.92 Million | 73.18% | 0.29x | $768.65 Million |
| ABVC Biopharma Inc (ABVC) | $29.08K | -111.02% | 1.35x | $26.26 Million |
| Abivax SA American Depositary Shares (ABVX) | $34.02 Million | -17.32% | 0.13x | $7.74 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $182.13 Million | -20.84% | 0.04x | $3.54 Billion |
About Chemomab Therapeutics Ltd DRC
Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of therapeutics for the treatment of fibrotic and inflammatory diseases. Its lead product candidate is nebokitug, a humanized monoclonal antibody that attenuates the basic function of CCL24 as a regulator of major inflammatory and fibrotic pathways, which has completed phase 2 clinical tri… Read more